Monopar Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 71.91 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 482.67M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Details
| Name | Monopar Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 22 |
| Founded | 2014 |
| Ipo Date | 2019-12-19 |
| Ceo | Chandler Robinson |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 8.00 |
| Isin | US61023L2079 |
| Cusip | 61023L207 |
| Cik | 1645469 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Christopher M. Starr Ph.D. | Co-Founder and Independent Executive Chairman of the Board |
| Quan Anh Vu | Chief Financial Officer, Principal accounting officer, Principal financial officer, Secretary and Treasurer |
| Andrew J. Cittadine M.B.A. | Chief Operating Officer |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer |
| Susan Rodriguez | Chief Commercial and Strategy Officer |
| Dr. Jeffrey D. Kent FACG, FACP, M.D. | Executive Vice President of Head of Medical Affairs |
Contact
| Address | 1000 Skokie Boulevard, Suite 350, Wilmette, Illinois 60091, United States |
| Phone | 847 388 0349 |
| Website | https://www.monopartx.com |